Biocon Closes $3bn Deal For Viatris Biosimilars
Cites ‘Historic Inflection Point’ For Biocon Biologics As Viatris Also Begins Transformation
Biocon has achieved a milestone after its Biocon Biologics subsidiary closed its $3bn deal to acquire the biosimilars business of longtime partner Viatris, in what management described as a “historic inflection point” for the Indian player.
